Radiotherapy for primary locally advanced breast cancer is to the whole breast, chest wall and the ipsilateral axillary, supraclavicular, infraclavicular and internal mammary nodes. Dose and schedule may vary from centre to centre, but not the basic principles. For example, the breast and chest wall may be treated tangentially and the draining lymph nodes irradiated in continuity by adjacent semi-opposed fields. Doses of up to 50 Gy are used with boosts approaching 20 Gy to sites of initially palpable disease. Local control is directly related to the radiation dose and inversely to the tumour volume (Arriagada et al., 1985) . In operable breast cancer, involvement of the highest axillary lymph node, the 'apex node', is associated with a poor prognosis after mastectomy (van Dongen, 1977) . In centres where apex node biopsy is performed in the staging of breast cancer, radiotherapy rather than surgery is the preferred treatment when the result is positive.
Several studies on prognostic factors in Stage III disease have been reported (Langlands et al., 1976; Rubens et al., 1977; Zucali et al., 1976 (Rubens et al., 1977) . This emphasises the importance of considering these variables in the analysis of clinical trials in locally advanced breast cancer.
In Stage III disease, the high incidence of subsequent distant metastases, reaching almost 70% in one series (Rubens et al., 1977) , accounts for the poor survival of patients treated by radiotherapy alone. This has led to the study of systemic treatment for its primary management.
Two early studies showed that chemotherapy with doxorubicin and vincristine before radiotherapy for locally advanced breast tumours gave a response frequency of about 70% and historical comparisons suggested that survival might be 'improved (De Lena et al., 1978; Rubens et al., 1980) . In Milan, this work was developed further in a randomised comparison of radiotherapy and radical mastectomy after primary chemotherapy (Valagussa et al., 1990) . There was no difference in either time to progressive disease or survival. But both groups received further chemotherapy after local treatment and this, compared to historical experience, was observed significantly to improve both end-points. Others also reported that adjuvant chemotherapy after primary radiotherapy resulted in significantly better local control and survival compared to radiotherapy alone in matched historical controls (Bruckman et al., 1979) . Systemic treatment following radiotherapy has now been tested in two randomised controlled clinical trials. The first was a three arm trial in which 118 patients were randomised to either radiotherapy alone, radiotherapy followed by 12 courses of cyclophosphamide, methotrexate and 5-fluorouracil (CMF), or courses of doxorubicin and vincristine alternating with CMF before and after radiotherapy (Schaake-Koning et al., 1985) . Local control and survival were not different in the three treatment arms. The second trial was conducted by the EORTC Breast Cancer Co-operative Group (Rubens et al., 1989) . Its aim was to test the independent and combined contributions of cytotoxic chemotherapy and endocrine therapy to radiotherapy in the primary treatment of locally advanced disease. In a factorial design, radiotherapy was the initial treatment for all patients after which they were randomly allocated to either radiotherapy alone, radiotherapy + endocrine therapy, radiotherapy + chemotherapy, or radiotherapy + endocrine therapy + chemotherapy. Endocrine treatment depended on menstrual status; premenopausal patients received ovarian irradiation and prednisolone whilst postmenopausal patients were given tamoxifen 10 mg bd for 5 years. Those randomised to receive chemotherapy had 12 cycles of CMF. In 363 evaluable patients, time to first progression was delayed significantly by either endocrine treatment or chemotherapy. Unexpectedly, the effect was due almost entirely to a delay in time to locoregional progression, for which the result was highly significant, rather than time to distant metastases. For survival, there was a trend in favour of the combination of hormone treatment and chemotherapy, but differences between the four treatments were not statistically significant.
As the ultimate aim of combining systemic treatment and radiotherapy is to eliminate micrometastases, the results of these trials are disappointing. Why systemic treatment should have a marked effect on the control of locoregional disease is uncertain. Possibly cells which metastasise have an intrinsically lower sensitivity to systemic treatment than cells which remain localised. Alternatively, radiotherapy could have sensitised residual loco-regional cancer cells to subsequent systemic treatment. Mathematical modelling of the results from the EORTC trial demonstrates that adjuvant systemic treatment after radiotherapy might reduce the number of residual local cancer cells by a factor of as much as 100 (Richards et al., 1988) .
The substantial chemosensitivity of locally advanced breast cancer observed in the earlier studies has led to the study of more intensive chemotherapy for the initial treatment of locally advanced disease. In a French study, 25 patients with diffuse inflammatory carcinomas were treated with high dose cyclophosphamide and 5-fluorouracil (Israel et al., 1986) . Twenty-four achieved operability and were treated by total mastectomy after which chemotherapy was resumed and, in the absence of recurrence, continued for 2 years. Median disease free interval was 46 months and estimated median survival more than 6 years; toxicity from treatment was high. Piccart et al. (1988) treated 59 patients with locally advanced breast cancer by combined radiotherapy, tamoxifen and chemotherapy (doxorubicin and vincristine alternating with CMF). All patients became operable and had total mastectomy and axillary clearance after which chemotherapy was resumed for 1 year. Treatment caused substantial toxicity; median survival was 4 years. Hortobagyi et al. (1988) described 126 patients with inoperable locally advanced disease treated with a combination of 5-fluorouracil, doxorubicin and cyclophosphamide. Response rate was 87% and, after three cycles, patients were treated by either radiotherapy or total mastectomy and axillary clearance followed by radiotherapy. Thereafter chemotherapy was resumed (methotrexate replacing doxorubicin) for approximately 1 year. The 5 year survival rate was 44%.
Results from these non-randomised studies suggest that intensive primary chemotherapy may lead to a better longterm outlook for patients presenting with locally advanced disease. But the earlier results which raised optimism for adjuvant systemic treatment were not confirmed in subsequent randomised trials and so these latest uncontrolled studies should be viewed with caution. Given the high toxicity of treatment and likely selection biases, confidence in these more aggressive approaches can only prevail once they have been substantiated in prospective randomised controlled trials. Only when very large differences are seen against historical controls can we have some certainty that progress has been made; this is not yet the case with the studies of primary chemotherapy reported so far. Undoubtedly, primary chemotherapy achieves a high clinical response rate in locally advanced breast cancer, but residual disease is found in the majority of mastectomy specimens (Israel et al., 1986; Piccart et al., 1988) . Nevertheless, despite this inability of chemotherapy reliably to induce pathological complete remission, it does facilitate implementation of radical local treatment. Whether or not this increases curability of locally advanced disease awaits to be determined in randomised trials. Meanwhile, pilot studies of potentially more effective approaches to primary chemotherapy need to be pursued. If higher doses of cytotoxic drugs could be delivered to tumours safely, higher tumour cell kill might be achieved. Intra-arterial chemotherapy has shown some promise (Stephens, 1990) , although not all experience has been favourable (Twelves et al., 1990) , and this method of treatment is not yet established. Intensification of systemic chemotherapy with bone marrow support by the use of haemopoietic growth factors or autologous bone marrow transplantation could be another way forward.
In judging the effectiveness of these intensive treatments in a disease of such high mortality it is essential to incorporate quality of life measures into the analysis of clinical trials. The concept of quality-adjusted time without symptoms of disease or toxicity from treatment (Q-TWiST) has been successfully applied to adjuvant systemic therapy for operable tumours (Goldhirsch et al., 1991) and could well be used to enhance the evaluation of future approaches to the treatment of locally advanced breast cancer.
